Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q6Q788
UPID:
APOA5_HUMAN
Alternative names:
Apolipoprotein A5; Regeneration-associated protein 3
Alternative UPACC:
Q6Q788; B0YIV9; Q3MIK6; Q6UWK9; Q9UBJ3
Background:
Apolipoprotein A-V, also known as Apolipoprotein A5 and Regeneration-associated protein 3, plays a crucial role in lipid metabolism. It is primarily associated with high-density lipoprotein (HDL) and to a lesser extent with very low-density lipoprotein (VLDL) and chylomicrons. This protein is a key determinant of plasma triglyceride levels, stimulating apo-CII lipoprotein lipase (LPL) triglyceride hydrolysis and inhibiting hepatic VLDL-TG production rate.
Therapeutic significance:
Apolipoprotein A-V is implicated in Hypertriglyceridemia 1 and Hyperlipoproteinemia 5, conditions characterized by elevated levels of triglycerides and VLDL, leading to an increased risk of heart disease, obesity, and pancreatitis. Understanding the role of Apolipoprotein A-V could open doors to potential therapeutic strategies for these lipid metabolism disorders.